Previous posters have done a good job on keeping this board informed. I am surprised that Yahoo Finance hasn't posted more stories on these analyst comments. If you notice at the end of the article, this analyst increased the estimated loss for FY 12. Since he raised the price target so dramatically, he must believe the extra expense is worthwhile.
Streetinsider.com article about Jeffries price target increase:
Jefferies boosted its price target DexCom (NASDAQ: DXCM) from $10 to $14 and reiterated its Buy rating following Q4 results.
The firm comments, "DXCM preannounced 4Q results of $22.4mn, reflecting a strong seasonal uptick in sensor utilization. 2012 is shaping up to be a year of investment as the company sets the stage for the Gen4 sensor launch."